Clinical Trial Update: Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study examining dual-orexin receptor antagonism to improve sleep and support abstinence in opioid use disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder
• Sleep Disorders

Snippet

Sponsor: Wayne State University | Conditions: Opioid-use Disorder, Sleep | Phase 2 | Status: TERMINATED